移动电话短信用于药物坚持心血管疾病的二次预防
Julie Redfern1,2, Qiang Tu1, Karice Hyun1,3
1School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
The Cochrane database of systematic reviews
|March 27, 2024
概括
手机短信对心血管疾病 (CVD) 患者的药物坚持和心血管事件减少产生不确定的影响. 需要更多高质量的研究来澄清益处和危害,特别是在低收入国家.
科学领域:
- 心脏病学 心脏病学
- 数字健康数字健康
- 公共卫生 公共卫生
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,低于最佳的药物服药增加了复发事件的风险.
- 移动电话短信为健康信息传递和行为改变提供了可扩展的方法,但其在心血管疾病患者中的有效性尚不确定.
- 本综述是2017年科克莱恩综述的更新,该综述检查了CVD二次预防的短信干预措施.
研究的目的:
- 评估手机短信干预措施的好处和危害,以改善心血管疾病患者的药物坚持.
- 为了比较短信与常规护理在减少心血管事件和改善临床结果方面的有效性.
主要方法:
- 包括18项随机对照试验 (RCT),其中8136名参与者被诊断患有已确定的动脉封闭事件.
- 干预涉及短信服务 (SMS) 或多媒体消息服务 (MMS),旨在改善二次心血管疾病预防的药物服药.
- 主要结局包括药物坚持,致命/非致命的心血管事件和结合心血管疾病事件;次要结局包括胆固醇,血压和心率.
主要成果:
- 关于短信对药物坚持的影响的证据非常不确定,研究显示出混合结果 (有益,减少或没有差异).
- 短信对致命的心血管事件 (低确定性证据),非致命事件 (非常低确定性) 和组合事件 (非常低确定性) 的影响很小或不存在.
- 干预对低密度脂蛋白胆固醇,静缩和静缩血压和心率几乎没有影响,证据确定性非常低.
结论:
- 目前的证据不足以确定短信是否能改善心血管疾病患者的服药能力或减少心血管事件.
- 短信干预措施对胆固醇,血压和心率等关键临床标志物的影响很小,甚至没有影响.
- 需要高质量的长期RCT,特别是在低收入国家,以确定手机短信对心脏病管理的有效性和安全性.
相关概念视频
01:17Antihypertensive Drugs: Action of β1 Blockers
441
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
441
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
01:25Errors occurring during blood pressure monitoring
720
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
720
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741